Proteome Systems signs agreement with Prince Henry's Institute for Ovarian Cancer Diagnostic Test


Sydney, Australia: Proteome Systems (ASX:PXL) today announced a collaboration with Prince Henry's Institute Medical Research (PHIMR) to combine their IP and expertise in ovarian cancer for the discovery and development of novel diagnostic markers.

  • If ovarian cancer is detected early there is a very good prognosis for full recovery. Currently, there is no test for early detection of ovarian cancer.
  • PXL has patented several protein and carbohydrate candidate markers for the development of an ovarian cancer diagnostic test.
  • Melbourne-based PHIMR has previously developed a test to detect ovarian cancer in post-menopausal woman, a significant sector of the target population.

Of all the gynaecologic cancers, ovarian malignancies represent the greatest clinical challenge. Around 1 in 56 women will develop ovarian cancer during their lifetime. Due to the absence of clear symptoms, ovarian cancer is usually detected when it has already spread beyond the ovary. At this relatively late stage the 5 year survival rate has decreased to ~30% while if the cancer is detected when confined to the ovary, the corresponding 5-year survival rate is >85%. This has led to the need to develop markers that can detect ovarian cancer at this early stage.

Proteome Systems has discovered and patented novel markers for epithelial ovarian cancer using its proprietary proteomic and glycoproteomic technology platforms. The company is actively seeking partnerships with academic and clinical groups with expertise in ovarian cancer to further expand its portfolio of ovarian cancer markers and clinically evaluate these for the development of a diagnostic test.

Associate Professor David Robertson leads the team at PHIMR that has previously developed a test to diagnose ovarian cancer (Robertson et al., 2002; Robertson and Oehler, 2005). The test is useful for initial diagnosis and monitoring recurrence of the disease in post-menopausal women, but it does not have the required specificity and sensitivity for application to diagnosis of early stage disease. Consequently, there is a need to identify new diagnostic markers for the development of a highly sensitive test for early stage ovarian cancer. PHIMR bring complementary technology in proteomics and reproductive biology, as well as clinical expertise in ovarian cancer, for the discovery and evaluation of new diagnostic markers.

Dr Jenny Harry, Deputy CEO and Head of Diagnostics at Proteome Systems said she "is delighted to be working with an outstanding team of scientists at PHIMR who also have strong commercial focus. The identification of diagnostic markers for the early stages of ovarian cancer will provide the basis for the development of a screening test and lead to a better prognosis for women with this disease. Women would be able to regularly screen for ovarian cancer as is currently possible for breast and cervical cancers."

Source: Eurekalert & others

Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
    Published on All rights reserved.